State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee
In March 2023 and 2024, a panel of international experts convened at the first and second Intercepting Blood Cancers (IBC) Workshops, with the aim of better appreciating the diagnostic challenges, pathophysiology, and potential therapeutic interventions for precursor malignant hematology conditions. Here, we report a summary of the proceedings from the sessions focused on monoclonal B-cell lymphocytosis (MBL)/chronic lymphocytic leukemia (CLL). We highlight four main content areas: biology of MBL, clinical implications of MBL, progression of MBL and transformation from indolent CLL to aggressive disease, and opportunities for therapeutic intervention in early CLL. We additionally outline key consensus management recommendations and research goals.
Authors
- Andy C. Rawstron (ORCID: https://orcid.org/0000-0003-0798-9790)
- Petra Langerbeins (ORCID: https://orcid.org/0000-0002-6654-0304)
- Sandrine Roulland (ORCID: https://orcid.org/0000-0003-2187-1959)
- Sameer Ashok Parikh (ORCID: https://orcid.org/0000-0002-3221-7314)
- José I. Martı́n-Subero (ORCID: https://orcid.org/0000-0001-8809-5195)
- Júlia Almeida (ORCID: https://orcid.org/0000-0003-3124-8917)
- Deborah Marie Stephens (ORCID: https://orcid.org/0000-0001-9188-5008)
- Dinis Pedro Calado (ORCID: https://orcid.org/0000-0001-8239-7184)
- Κώστας Σταματόπουλος (ORCID: https://orcid.org/0000-0001-8529-640X)
- Miguel Alcoceba (ORCID: https://orcid.org/0000-0002-3819-4846)
- Erin Michelle Parry (ORCID: https://orcid.org/0000-0002-3382-9769)
- Inhye E. Ahn (ORCID: https://orcid.org/0000-0003-3717-287X)
- Jessica Okosun (ORCID: https://orcid.org/0000-0001-6021-5044)
- Carsten Utoft Niemann (ORCID: https://orcid.org/0000-0001-9880-5242)
- Hendrik Veelken (ORCID: https://orcid.org/0000-0002-9108-3125)
- Matthew Steven Davids (ORCID: https://orcid.org/0000-0003-4529-2003)
- Susan L. Slager (ORCID: https://orcid.org/0000-0002-5173-4712)
- Christine E. Ryan (ORCID: https://orcid.org/0000-0003-2588-1943)
- Anton W. Langerak (ORCID: https://orcid.org/0000-0002-2078-3220)
- Tait Shanafelt
- Aswin Sekar (ORCID: https://orcid.org/0000-0003-0406-0935)
- Paolo Ghia (ORCID: https://orcid.org/0000-0003-3750-7342)
- Alberto Órfão (ORCID: https://orcid.org/0000-0002-0007-7230)
Institutions
- University of North Carolina at Chapel Hill (US)
- Centre National de la Recherche Scientifique (FR)
- Mayo Clinic (US)
- Vita-Salute San Raffaele University (IT)
- Inserm (FR)
- Queen Mary University of London (GB)
- University of Cologne (DE)
- Universidad de Salamanca (ES)
- Aix-Marseille Université (FR)
- Leeds Teaching Hospitals NHS Trust (GB)
- Leiden University Medical Center (NL)
- The Francis Crick Institute (GB)
- Instituto de Salud Carlos III (ES)
- Erasmus MC (NL)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Düsseldorf University Hospital (DE)
- Dana-Farber Cancer Institute (US)
- Mayo Clinic in Arizona (US)
- Cancer Research Center (US)
- IRCCS Ospedale San Raffaele (IT)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Centre for Research and Technology Hellas (GR)
- Centro de Investigación del Cáncer (ES)
- Centre d’Immunologie de Marseille-Luminy (FR)
- University Hospital Cologne (DE)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Heinrich Heine University Düsseldorf (DE)
- CytRx (United States) (US)
- Erasmus University Rotterdam (NL)
- Stanford University (US)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1038/s41408-025-01341-6
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 3.25
Funders
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Regeneron Pharmaceuticals
- Associazione Italiana per la Ricerca sul Cancro
- National Institutes of Health
- Janssen Pharmaceuticals